Cellectis S.A. (CLLS) 32.61 $CLLS
100 M&A Focused Medical Devices/Technology/Supplies Companies 2015
M2 - Wed Apr 15, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4bk7/manda_focused) has announced the addition of the "M&A Focused Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. This report newly launched report identifies 100 M&A Focused medical devices/technology/supplies companies and covers various aspects of these 100 companies including news, financial/non-financial information, and stock market analysis. Alliances and partnerships have traditionally been used to help companies reduce their funding and resource burden and provide potential upside. These non-dilutive sources of funding can take many forms and warrant a second look in the light of today's difficult economy. A panel of seasoned medical device executives will analyze several recent partnering deals and contemplate their usefulness as alternative funding sources. Practical take-away include: how to integrate product co-development into your innovation strategy, understanding the key differences in structuring partnership deals with large and small companies and universities and/or research centers, understanding the pitfalls, risks and opportunities that these partnering models present, and understanding how to leverage these relationships to create win-win scenarios to the benefit all participants. M&A environment in 2015 is anticipated to continue its strong growth trends. Strategic and private equity acquisition appetites for strong healthcare companies continue to grow and this offers tremendous liquidity opportunities for business owners. As strategic acquirers become increasingly aggressive in their pursuit of new sources of growth, the robust capital markets welcome the next wave of growth companies. Despite significant challenges in reimbursement and other operating factors, many healthcare providers continue to grow profitably by scaling their businesses. While this growth comes at a significant cost to gross margins, we see efficient companies continuing to generate strong overall profits and hence, attractive acquisition opportunities. Report Highlights: - M&A Focused 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of M&A Focused medical devices/technology/supplies companies with foreign companies - International presence of M&A Focused medical devices/technology/supplies companies - Key R&D activities by M&A Focused medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of M&A Focused Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 5 Years: Leading 25 M&A Focused Medical Devices/Technology/Supplies Companies 3: Key News of M&A Focused Medical Devices/Technology/Supplies Companies for Year 2014 4: Important Alliances of M&A Focused Medical Devices/Technology/Supplies Companies with Foreign Companies 5: Research and Development Activities by M&A Focused Medical Devices/Technology/Supplies Companies 6: International Presence of M&A Focused Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of M&A Focused Medical Devices/Technology/Supplies Companies Companies Mentioned Sample list of company names included in this industry report: - 3M Company (United States) - Abaxis Inc (United States) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alfresa Pharma Corp (Japan) - Andon Health Company Limited (China) - Angiodynamics, Inc. (United States) - Anteo Diagnostics Limited (Australia) - Atcor Medical Holdings Ltd (Australia) - Azure Healthcare Ltd. (Australia) - Bio Rad Laboratories Incorporated (United States) - Bruker Corporation (United States) - Capitol Health Ltd (Australia) - Carefusion Corporation (United States) - Carl Zeiss Co., Ltd. (Japan) - Cellectis SA (France) - Coherent Incorporated (United States) - Cooper Companies Inc. (United States) - Corgenix Medical Corporation (United States) - Dynasil Corporation Of America (United States) - Heartware International Inc (Australia) - Hill-Rom Holdings, Incorporation (United States) - Jeol Limited (Japan) - Paragon Care Limited (Australia) - Smith & Nephew PLC (United Kingdom) - Tecan Group AG (Switzerland) - Veracyte, Inc. (United States) - Vitrolife AB (Sweden) - Volcano Corporation (United States) For more information visit http://www.researchandmarkets.com/research/7d...da_focused
MMM: 158.99 (-0.67), COO: 181.75 (-1.24), SNN: 35.76 (+0.44), VCYT: 9.63 (+0.40), ABAX: 63.62 (+0.31), DYSL: 1.40 (unch), VOLC: 17.99 (+0.01), CLLS: 32.61 (-0.07), COHR: 65.14 (-1.57), HRC: 51.94 (+0.03)
Heat Biologics is an Opportunity Among Soaring Immunotherapy Biotech Valuations
ACCESSWIRE - Tue Apr 14, 11:17AM CDT
NEW YORK, NY / ACCESSWIRE / April 14, 2015 / Vaccination, in medical terminology, is injection of a disease-causing microorganism that stimulates the immune system to fight against infection, using the body's own defense mechanisms. Vaccination has all but wiped out polio, tetanus, chicken pox and measles with non-live proteins that lead to an antibody response to promote internal, natural healing. A new type of immunotherapy has emerged in recent years, led by Heat Biologics, Inc. (HTBX: NASDAQ), using live cellular material to cause an immune reaction with a more potent form of white blood cells that seek out and destroy cancer.
HTBX: 6.89 (-0.71), CLLS: 32.61 (-0.07)
Cellectis Announces Presentations at Upcoming Conferences
Business Wire - Thu Apr 09, 5:24PM CDT
Regulatory News:
CLLS: 32.61 (-0.07)
Cellectis Opens Labs and Offices in Manhattan, New York
Business Wire - Wed Apr 08, 5:17PM CDT
Regulatory News:
CLLS: 32.61 (-0.07)
Week Ahead: 1 IPO During The Week Of March 9 With Blackstone's First Deal Of The Year
Renaissance Capital IPO Research - at Seeking Alpha - Fri Apr 03, 1:23AM CDT
The third tech IPO of 2015 crumbled last week , and now all eyes are on construction supply company Summit Materials, the week's only IPO and the year's first LBO. • 1 US IPO on the calendar : Blackstone's Summit set to raise $400 million ...
AGMX: (), ETSY: 25.58 (-0.04), OPGN: (), SEDG: 24.89 (+0.10), IDGX: (), VIRT: 22.16 (-0.44), SUM: 23.73 (+0.66), CLLS: 32.61 (-0.07), VLRX: (), GDDY: 25.63 (+0.58)
Nasdaq Leads U.S. Exchanges for IPOs in 2015
GlobeNewswire - Wed Apr 01, 11:06AM CDT
Nasdaq (Nasdaq:NDAQ) announced that it welcomed 43 new listings, including 27 initial public offerings (IPOs) on The Nasdaq Stock Market in the first quarter of 2015, more than double the number of IPOs of any other U.S. exchange. Combined proceeds raised by Nasdaq's first quarter IPOs totaled approximately $2.8 billion. Nasdaq remains the leading U.S. exchange for healthcare, financial and venture capital-backed IPOs and welcomed the largest technology deal year-to-date with Inovalon Holdings (Nasdaq:INOV). In the first quarter Nasdaq's IPOs have returned on average an increase of 23 percent from their offer price, above the market average return for all U.S. IPOs of 21 percent.
SEDG: 24.89 (+0.10), AMD: 2.30 (-0.03), ONCE: 61.39 (-0.66), CLLS: 32.61 (-0.07), INOV: 26.67 (-0.32), NDAQ: 48.57 (-1.19), TW: 128.79 (-0.36)
This Small Biotech Got A Booster Shot On CAR-T Deal
at Investor's Business Daily - Mon Mar 30, 1:15PM CDT
Shares of Intrexon (XON) gapped up on news that the synthetic biotech had formed a collaboration and licensing deal with biopharmaceutical firm Merck KGaA of Darmstadt, Germany, to develop and commercialize CAR-T therapies. Intrexon shares rose 9% to...
ZIOP: 10.81 (-0.39), BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), MRK: 57.60 (+0.09), CLLS: 32.61 (-0.07), XON: 44.10 (-0.91), AMGN: 167.91 (-1.26), JUNO: 56.66 (-1.06)
U.S. IPO Weekly Recap: SolarEdge Shines While Other IPOs Fall Flat
Renaissance Capital IPO Research - at Seeking Alpha - Sat Mar 28, 6:39AM CDT
Four companies publicly listed on US markets during the last full week of the first quarter, raising $510 million. Solar tech provider SolarEdge outshined its peers while mega biotech Cellectis saw speculators jump in before the IPO and then quickly...
WOWO: 9.35 (+0.51), SEDG: 24.89 (+0.10), ENPH: 13.47 (-0.43), TANH: 12.29 (+0.54), VRAY: (), FSB: 20.90 (+0.15), CLLS: 32.61 (-0.07), VLRX: (), JCAP: 21.69 (+0.32), JUNO: 56.66 (-1.06), PUMP: (), GDDY: 25.63 (+0.58)
Seeking Alpha's Biotech Weekly: Gilead Cardiac Flap, Ohr Sinks, MEI Selloff, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 27, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ABMD: 68.83 (-0.74), BIIB: 401.71 (-28.57), BMY: 65.80 (-0.20), GSK: 46.59 (+0.28), HUM: 182.35 (+0.44), MEIP: 2.16 (-0.02), DVA: 83.91 (+0.50), PFS: 18.06 (-0.62), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), CLLS: 32.61 (-0.07), HHS: 7.72 (+0.04), OHRP: 2.94 (+0.12), THRX: 17.92 (+0.46), REGN: 480.09 (+0.01)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 8:13AM CDT
EXXI: 4.16 (+0.06), OTIV: 1.50 (-0.10), CNAT: 6.66 (-0.15), EXAS: 21.98 (-1.08), WGBS: 4.62 (+0.05), FIVE: 36.04 (+0.10), ROSG: 3.72 (+0.06), NVAX: 8.58 (-0.07), RHT: 76.83 (-0.02), SCMP: 21.09 (-0.31), CLLS: 32.61 (-0.07), MAGS: 4.90 (unch), VBLT: 4.23 (+0.07), SNDK: 67.92 (-0.84)
IPO Stock Watch: CAR-T Maker Cellectis Slips In Debut
at Investor's Business Daily - Wed Mar 25, 3:59PM CDT
French biotech Cellectis (CLLS) slipped 5.3% in its Nasdaq debut Wednesday to close at 39.30 after enlarging its deal size to $229 million. Cellectis sold 5.5 million shares at $41.50 each, the price being essentially determined by where the stock...
BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), PFE: 35.27 (-0.09), CLLS: 32.61 (-0.07), JUNO: 56.66 (-1.06)
Photo Release -- Nasdaq Welcomes Cellectis SA (Nasdaq: CLLS) to The Nasdaq Stock Market
GlobeNewswire - Wed Mar 25, 10:05AM CDT
Nasdaq (Nasdaq:NDAQ) announced that trading of Cellectis SA (Nasdaq:CLLS) commenced on The Nasdaq Stock Market on March 25, 2015.
CLLS: 32.61 (-0.07), NDAQ: 48.57 (-1.19)
Cellectis debuts today
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 6:13AM CDT
CLLS: 32.61 (-0.07)
Cellectis SA (Nasdaq: CLLS) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO
GlobeNewswire - Wed Mar 25, 5:00AM CDT
What:
CLLS: 32.61 (-0.07), NDAQ: 48.57 (-1.19)
Cellectis Appears To Be Another Great CAR T-Cell Pharma Company
APBK Capital - at Seeking Alpha - Tue Mar 24, 1:05PM CDT
CLLS: 32.61 (-0.07)
Week Ahead: Up To 9 IPOs During The Week Of March 23 Led By A Billion-Dollar Biotech
Renaissance Capital IPO Research - at Seeking Alpha - Mon Mar 23, 12:41AM CDT
In the last full week of the first quarter , the IPO market could see a billion-dollar cancer biotech and a producer of optimized solar power technology. Three health care IPOs: a mega biotech and two small medical devices Pre-clinical...
WOWO: 9.35 (+0.51), SEDG: 24.89 (+0.10), ENPH: 13.47 (-0.43), TANH: 12.29 (+0.54), FSB: 20.90 (+0.15), VRAY: (), AVNU: 11.94 (+0.29), CLLS: 32.61 (-0.07), VLRX: (), GDDY: 25.63 (+0.58)
Seeking Alpha's Biotech Weekly: Biogen's Plaque Attack, Amgen Or Gilead?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
TRVN: 6.69 (-0.30), MDT: 77.61 (-0.89), CLDX: 30.10 (+0.19), FOMX: 10.46 (-0.44), AMGN: 167.91 (-1.26), AET: 108.82 (-0.08), NKTR: 10.77 (-0.29), CELG: 118.71 (+2.62), HUM: 182.35 (+0.44), CANF: 2.17 (+0.02), ANTM: 154.28 (+0.08), NVO: 56.65 (+0.44), GILD: 103.69 (-1.52), GERN: 4.30 (-0.03), AZN: 71.79 (-1.34), CLLS: 32.61 (-0.07), WCG: 83.50 (+0.31), FOLD: 12.25 (-0.05), REGN: 480.09 (+0.01), CUR: 1.94 (-0.06)
Coronado's Latest Opportunistic Move: CAR-T Therapy
EP Vantage - Seeking Alpha - Thu Mar 19, 2:03PM CDT
Give Coronado Biosciences ’ (NASDAQ: CNDO ) management team top marks for brazen opportunism. After seeing its porcine whipworm egg-based project fail in Crohn's disease, the group is getting into some of biotech's hottest areas, earlier this...
BLCM: 27.88 (-0.46), CNDO: 3.97 (-0.14), CLLS: 32.61 (-0.07)
CAR-T cancer therapy stocks head north
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 12:29PM CDT
BLUE: 136.26 (-3.82), ZIOP: 10.81 (-0.39), BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), CNDO: 3.97 (-0.14), CLLS: 32.61 (-0.07), JUNO: 56.66 (-1.06)
100 M&A Focused Medical Devices/Technology/Supplies Companies 2015
M2 - Wed Apr 15, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4bk7/manda_focused) has announced the addition of the "M&A Focused Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. This report newly launched report identifies 100 M&A Focused medical devices/technology/supplies companies and covers various aspects of these 100 companies including news, financial/non-financial information, and stock market analysis. Alliances and partnerships have traditionally been used to help companies reduce their funding and resource burden and provide potential upside. These non-dilutive sources of funding can take many forms and warrant a second look in the light of today's difficult economy. A panel of seasoned medical device executives will analyze several recent partnering deals and contemplate their usefulness as alternative funding sources. Practical take-away include: how to integrate product co-development into your innovation strategy, understanding the key differences in structuring partnership deals with large and small companies and universities and/or research centers, understanding the pitfalls, risks and opportunities that these partnering models present, and understanding how to leverage these relationships to create win-win scenarios to the benefit all participants. M&A environment in 2015 is anticipated to continue its strong growth trends. Strategic and private equity acquisition appetites for strong healthcare companies continue to grow and this offers tremendous liquidity opportunities for business owners. As strategic acquirers become increasingly aggressive in their pursuit of new sources of growth, the robust capital markets welcome the next wave of growth companies. Despite significant challenges in reimbursement and other operating factors, many healthcare providers continue to grow profitably by scaling their businesses. While this growth comes at a significant cost to gross margins, we see efficient companies continuing to generate strong overall profits and hence, attractive acquisition opportunities. Report Highlights: - M&A Focused 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of M&A Focused medical devices/technology/supplies companies with foreign companies - International presence of M&A Focused medical devices/technology/supplies companies - Key R&D activities by M&A Focused medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of M&A Focused Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 5 Years: Leading 25 M&A Focused Medical Devices/Technology/Supplies Companies 3: Key News of M&A Focused Medical Devices/Technology/Supplies Companies for Year 2014 4: Important Alliances of M&A Focused Medical Devices/Technology/Supplies Companies with Foreign Companies 5: Research and Development Activities by M&A Focused Medical Devices/Technology/Supplies Companies 6: International Presence of M&A Focused Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of M&A Focused Medical Devices/Technology/Supplies Companies Companies Mentioned Sample list of company names included in this industry report: - 3M Company (United States) - Abaxis Inc (United States) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alfresa Pharma Corp (Japan) - Andon Health Company Limited (China) - Angiodynamics, Inc. (United States) - Anteo Diagnostics Limited (Australia) - Atcor Medical Holdings Ltd (Australia) - Azure Healthcare Ltd. (Australia) - Bio Rad Laboratories Incorporated (United States) - Bruker Corporation (United States) - Capitol Health Ltd (Australia) - Carefusion Corporation (United States) - Carl Zeiss Co., Ltd. (Japan) - Cellectis SA (France) - Coherent Incorporated (United States) - Cooper Companies Inc. (United States) - Corgenix Medical Corporation (United States) - Dynasil Corporation Of America (United States) - Heartware International Inc (Australia) - Hill-Rom Holdings, Incorporation (United States) - Jeol Limited (Japan) - Paragon Care Limited (Australia) - Smith & Nephew PLC (United Kingdom) - Tecan Group AG (Switzerland) - Veracyte, Inc. (United States) - Vitrolife AB (Sweden) - Volcano Corporation (United States) For more information visit http://www.researchandmarkets.com/research/7d...da_focused
MMM: 158.99 (-0.67), COO: 181.75 (-1.24), SNN: 35.76 (+0.44), VCYT: 9.63 (+0.40), ABAX: 63.62 (+0.31), DYSL: 1.40 (unch), VOLC: 17.99 (+0.01), CLLS: 32.61 (-0.07), COHR: 65.14 (-1.57), HRC: 51.94 (+0.03)
Heat Biologics is an Opportunity Among Soaring Immunotherapy Biotech Valuations
ACCESSWIRE - Tue Apr 14, 11:17AM CDT
NEW YORK, NY / ACCESSWIRE / April 14, 2015 / Vaccination, in medical terminology, is injection of a disease-causing microorganism that stimulates the immune system to fight against infection, using the body's own defense mechanisms. Vaccination has all but wiped out polio, tetanus, chicken pox and measles with non-live proteins that lead to an antibody response to promote internal, natural healing. A new type of immunotherapy has emerged in recent years, led by Heat Biologics, Inc. (HTBX: NASDAQ), using live cellular material to cause an immune reaction with a more potent form of white blood cells that seek out and destroy cancer.
HTBX: 6.89 (-0.71), CLLS: 32.61 (-0.07)
Cellectis Announces Presentations at Upcoming Conferences
Business Wire - Thu Apr 09, 5:24PM CDT
Regulatory News:
CLLS: 32.61 (-0.07)
Cellectis Opens Labs and Offices in Manhattan, New York
Business Wire - Wed Apr 08, 5:17PM CDT
Regulatory News:
CLLS: 32.61 (-0.07)
Week Ahead: 1 IPO During The Week Of March 9 With Blackstone's First Deal Of The Year
Renaissance Capital IPO Research - at Seeking Alpha - Fri Apr 03, 1:23AM CDT
The third tech IPO of 2015 crumbled last week , and now all eyes are on construction supply company Summit Materials, the week's only IPO and the year's first LBO. • 1 US IPO on the calendar : Blackstone's Summit set to raise $400 million ...
AGMX: (), ETSY: 25.58 (-0.04), OPGN: (), SEDG: 24.89 (+0.10), IDGX: (), VIRT: 22.16 (-0.44), SUM: 23.73 (+0.66), CLLS: 32.61 (-0.07), VLRX: (), GDDY: 25.63 (+0.58)
Nasdaq Leads U.S. Exchanges for IPOs in 2015
GlobeNewswire - Wed Apr 01, 11:06AM CDT
Nasdaq (Nasdaq:NDAQ) announced that it welcomed 43 new listings, including 27 initial public offerings (IPOs) on The Nasdaq Stock Market in the first quarter of 2015, more than double the number of IPOs of any other U.S. exchange. Combined proceeds raised by Nasdaq's first quarter IPOs totaled approximately $2.8 billion. Nasdaq remains the leading U.S. exchange for healthcare, financial and venture capital-backed IPOs and welcomed the largest technology deal year-to-date with Inovalon Holdings (Nasdaq:INOV). In the first quarter Nasdaq's IPOs have returned on average an increase of 23 percent from their offer price, above the market average return for all U.S. IPOs of 21 percent.
SEDG: 24.89 (+0.10), AMD: 2.30 (-0.03), ONCE: 61.39 (-0.66), CLLS: 32.61 (-0.07), INOV: 26.67 (-0.32), NDAQ: 48.57 (-1.19), TW: 128.79 (-0.36)
This Small Biotech Got A Booster Shot On CAR-T Deal
at Investor's Business Daily - Mon Mar 30, 1:15PM CDT
Shares of Intrexon (XON) gapped up on news that the synthetic biotech had formed a collaboration and licensing deal with biopharmaceutical firm Merck KGaA of Darmstadt, Germany, to develop and commercialize CAR-T therapies. Intrexon shares rose 9% to...
ZIOP: 10.81 (-0.39), BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), MRK: 57.60 (+0.09), CLLS: 32.61 (-0.07), XON: 44.10 (-0.91), AMGN: 167.91 (-1.26), JUNO: 56.66 (-1.06)
U.S. IPO Weekly Recap: SolarEdge Shines While Other IPOs Fall Flat
Renaissance Capital IPO Research - at Seeking Alpha - Sat Mar 28, 6:39AM CDT
Four companies publicly listed on US markets during the last full week of the first quarter, raising $510 million. Solar tech provider SolarEdge outshined its peers while mega biotech Cellectis saw speculators jump in before the IPO and then quickly...
WOWO: 9.35 (+0.51), SEDG: 24.89 (+0.10), ENPH: 13.47 (-0.43), TANH: 12.29 (+0.54), VRAY: (), FSB: 20.90 (+0.15), CLLS: 32.61 (-0.07), VLRX: (), JCAP: 21.69 (+0.32), JUNO: 56.66 (-1.06), PUMP: (), GDDY: 25.63 (+0.58)
Seeking Alpha's Biotech Weekly: Gilead Cardiac Flap, Ohr Sinks, MEI Selloff, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 27, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ABMD: 68.83 (-0.74), BIIB: 401.71 (-28.57), BMY: 65.80 (-0.20), GSK: 46.59 (+0.28), HUM: 182.35 (+0.44), MEIP: 2.16 (-0.02), DVA: 83.91 (+0.50), PFS: 18.06 (-0.62), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), CLLS: 32.61 (-0.07), HHS: 7.72 (+0.04), OHRP: 2.94 (+0.12), THRX: 17.92 (+0.46), REGN: 480.09 (+0.01)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 8:13AM CDT
EXXI: 4.16 (+0.06), OTIV: 1.50 (-0.10), CNAT: 6.66 (-0.15), EXAS: 21.98 (-1.08), WGBS: 4.62 (+0.05), FIVE: 36.04 (+0.10), ROSG: 3.72 (+0.06), NVAX: 8.58 (-0.07), RHT: 76.83 (-0.02), SCMP: 21.09 (-0.31), CLLS: 32.61 (-0.07), MAGS: 4.90 (unch), VBLT: 4.23 (+0.07), SNDK: 67.92 (-0.84)
IPO Stock Watch: CAR-T Maker Cellectis Slips In Debut
at Investor's Business Daily - Wed Mar 25, 3:59PM CDT
French biotech Cellectis (CLLS) slipped 5.3% in its Nasdaq debut Wednesday to close at 39.30 after enlarging its deal size to $229 million. Cellectis sold 5.5 million shares at $41.50 each, the price being essentially determined by where the stock...
BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), PFE: 35.27 (-0.09), CLLS: 32.61 (-0.07), JUNO: 56.66 (-1.06)
Photo Release -- Nasdaq Welcomes Cellectis SA (Nasdaq: CLLS) to The Nasdaq Stock Market
GlobeNewswire - Wed Mar 25, 10:05AM CDT
Nasdaq (Nasdaq:NDAQ) announced that trading of Cellectis SA (Nasdaq:CLLS) commenced on The Nasdaq Stock Market on March 25, 2015.
CLLS: 32.61 (-0.07), NDAQ: 48.57 (-1.19)
Cellectis debuts today
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 6:13AM CDT
CLLS: 32.61 (-0.07)
Cellectis SA (Nasdaq: CLLS) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO
GlobeNewswire - Wed Mar 25, 5:00AM CDT
What:
CLLS: 32.61 (-0.07), NDAQ: 48.57 (-1.19)
Cellectis Appears To Be Another Great CAR T-Cell Pharma Company
APBK Capital - at Seeking Alpha - Tue Mar 24, 1:05PM CDT
CLLS: 32.61 (-0.07)
Week Ahead: Up To 9 IPOs During The Week Of March 23 Led By A Billion-Dollar Biotech
Renaissance Capital IPO Research - at Seeking Alpha - Mon Mar 23, 12:41AM CDT
In the last full week of the first quarter , the IPO market could see a billion-dollar cancer biotech and a producer of optimized solar power technology. Three health care IPOs: a mega biotech and two small medical devices Pre-clinical...
WOWO: 9.35 (+0.51), SEDG: 24.89 (+0.10), ENPH: 13.47 (-0.43), TANH: 12.29 (+0.54), FSB: 20.90 (+0.15), VRAY: (), AVNU: 11.94 (+0.29), CLLS: 32.61 (-0.07), VLRX: (), GDDY: 25.63 (+0.58)
Seeking Alpha's Biotech Weekly: Biogen's Plaque Attack, Amgen Or Gilead?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
TRVN: 6.69 (-0.30), MDT: 77.61 (-0.89), CLDX: 30.10 (+0.19), FOMX: 10.46 (-0.44), AMGN: 167.91 (-1.26), AET: 108.82 (-0.08), NKTR: 10.77 (-0.29), CELG: 118.71 (+2.62), HUM: 182.35 (+0.44), CANF: 2.17 (+0.02), ANTM: 154.28 (+0.08), NVO: 56.65 (+0.44), GILD: 103.69 (-1.52), GERN: 4.30 (-0.03), AZN: 71.79 (-1.34), CLLS: 32.61 (-0.07), WCG: 83.50 (+0.31), FOLD: 12.25 (-0.05), REGN: 480.09 (+0.01), CUR: 1.94 (-0.06)
Coronado's Latest Opportunistic Move: CAR-T Therapy
EP Vantage - Seeking Alpha - Thu Mar 19, 2:03PM CDT
Give Coronado Biosciences ’ (NASDAQ: CNDO ) management team top marks for brazen opportunism. After seeing its porcine whipworm egg-based project fail in Crohn's disease, the group is getting into some of biotech's hottest areas, earlier this...
BLCM: 27.88 (-0.46), CNDO: 3.97 (-0.14), CLLS: 32.61 (-0.07)
CAR-T cancer therapy stocks head north
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 12:29PM CDT
BLUE: 136.26 (-3.82), ZIOP: 10.81 (-0.39), BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), CNDO: 3.97 (-0.14), CLLS: 32.61 (-0.07), JUNO: 56.66 (-1.06)
